Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas
Publication
, Conference
Kelly, KR; Persky, DO; Mahadevan, D; Miller, TP; Puvvada, SD; McDonagh, K; Hayslip, J; Park, SI; Ruan, J; Rosen, PJ; Iyer, SP; Stefanovic, A ...
Published in: Blood
November 15, 2013
Duke Scholars
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 15, 2013
Volume
122
Issue
21
Start / End Page
3027 / 3027
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Kelly, K. R., Persky, D. O., Mahadevan, D., Miller, T. P., Puvvada, S. D., McDonagh, K., … Friedberg, J. W. (2013). Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas. In Blood (Vol. 122, pp. 3027–3027). American Society of Hematology. https://doi.org/10.1182/blood.v122.21.3027.3027
Kelly, Kevin R., Daniel O. Persky, Daruka Mahadevan, Thomas P. Miller, Soham D. Puvvada, Kevin McDonagh, John Hayslip, et al. “Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas.” In Blood, 122:3027–3027. American Society of Hematology, 2013. https://doi.org/10.1182/blood.v122.21.3027.3027.
Kelly KR, Persky DO, Mahadevan D, Miller TP, Puvvada SD, McDonagh K, et al. Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas. In: Blood. American Society of Hematology; 2013. p. 3027–3027.
Kelly, Kevin R., et al. “Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas.” Blood, vol. 122, no. 21, American Society of Hematology, 2013, pp. 3027–3027. Crossref, doi:10.1182/blood.v122.21.3027.3027.
Kelly KR, Persky DO, Mahadevan D, Miller TP, Puvvada SD, McDonagh K, Hayslip J, Park SI, Ruan J, Rosen PJ, Iyer SP, Stefanovic A, Zhang B, Zhou X, Ullmann CD, Leonard EJ, Friedberg JW. Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas. Blood. American Society of Hematology; 2013. p. 3027–3027.
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 15, 2013
Volume
122
Issue
21
Start / End Page
3027 / 3027
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology